ESC Premium Access

Short term effect of SGLT2 inhibitor, Dapagliflozin added on to standard therapy in decompensated heart failure patients with diabetes mellitus

Congress Presentation

About the speaker

Doctor Masaki Nakagaito

University of Toyama, Toyama (Japan)
0 follower

6 more presentations in this session

Do beta-blockers improve one-year survival in heart failure patients with atrial fibrillation? Results from the ESC-HF Registry

Speaker: Doctor K. Ozieranski (Warsaw, PL)


Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation in the PREFER in AF registry

Speaker: Associate Professor J. Siller-Matula (Vienna, AT)


Association between serum potassium and clinical outcomes in UK patients with heart failure

Speaker: Ms L. Qin (Gaithersburg, US)


Presence of micro- and macroalbuminuria and association with cardiac mechanics in type 2 diabetes

Speaker: Doctor P. Jorgensen (Hellerup, DK)


Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c

Speaker: Doctor D. Fitchett (Toronto, CA)


Access the full session

Fresh look at heart failure

Speakers: Doctor M. Nakagaito, Doctor K. Ozieranski, Associate Professor J. Siller-Matula, Ms L. Qin, Doctor P. Jorgensen...

About the event


ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb